Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.

Biotechnology

Pharmaceutical

Calliditas Therapeutics

Renee Aguiar-Lucander

Catherine Andrus

Teona Pipiya Johnson

Sandra Frithiof

Russell Jones

Richard Philipson

Mark Biddle

Krassimir Mitchev

Karin Göhlin

Johan Häggblad

Jeanette Roos

James Hoffman, CPA, CGMA

Henrik Nilsson

Fredrik Johansson

Christopher Ngai

Frank Bringstrup

The Sales and Marketing team at Calliditas Therapeutics is dedicated to promoting and commercializing Nefecon, a targeted treatment for IgA nephropathy. The team engages with healthcare professionals, manages relationships with key accounts, and ensures access to this innovative therapy for patients in need. Through strategic marketing initiatives and sales training, the team aims to effectively educate stakeholders about the benefits of Nefecon while navigating reimbursement challenges in the United States.

Sales and Marketing

Leadership Team

Sales and Marketing

About

Team members

Other teams at Calliditas Therapeutics

Leadership Team

Leadership Team